QIAGEN powered by

QCI Precision Insights

Reimagine your clinical interpretation with same day, expert variant classification services tailored to your oncology panel

Provide patient-specific reports in less time with greater confidence

With the rapidly increasing volume of clinical and scientific data, and hundreds of drugs currently in clinical trials, the task of interpreting molecular test results has become increasingly challenging.

QCI Precision Insights provides scalable, cost-effective genomic clinical decision support that delivers concise oncologist-reviewed evidence for each biomarker in the context of the cancer sub-type and available therapeutics matched by country.

Trusted to interpret over 190,000 patient cases

QCI Precision Insight’s team of experts has interpreted more than 190,000 tumor samples. With this service, you can improve test turnaround time by 85-90% without the need for extra staffing.

Now available in Europe

Molecular pathology labs in Europe can now leverage QCI Precision Insights. The service now includes European Society for Medical Oncology (ESMO) guidelines, European LeukemiaNet (ELN) recommendations, and European Medicines Agency (EMA) approved oncology drugs. 

Read the press release         View sample report

Accelerate oncology precision medicine

Send your variants to QCI Precision Insights and receive expert-curated interpretation content in minutes

Accelerate test turnaround time

Submit your variant calling files (VCFs) and receive customized, oncologist-reviewed, variant-specific content within minutes.

Receive up-to-date insights

Deliver reports with expert summaries of the latest biological, diagnostic, prognostic, and therapeutic evidence in context of the tumor profile, treatment, and regional clinical trials.

Leave the heavy-lifting to QIAGEN

For rare or novel variants, enlist QIAGEN’s expert MD and PhD variant scientist team to perform the in-depth research, curation and interpretation for you.

“We use QIAGEN's clinical interpretation services for a simple reason: the results matter. We know we can rely on QCI Precision Insights for a thorough and thoughtful analysis, and they are always available at the other end of the phone to discuss the latest abstracts and publications regarding new genomic targets and treatments.”

Rick Lanman, MD
Chief Medical Officer, Guardant Health, Inc.

Case-specific reports

  • Molecularly relevant treatment options

    Deliver patient-specific reports comprising a filtered list of the patient’s actionable variants with respect to potential treatment options. 

  • Potential interactions

    Minimize risk with identified potential interactions with drug sensitivity, resistance, or implications. 

  • Professional guideline levels of evidence

    Ensure a more consistent report format that clearly conveys the degree of importance with AMP/ASCO/CAP (United States) and ESMO (Europe) levels of evidence for variant classification.

  • Clinical trials by clinical significance and geographic specificity

    Provide the most relevant treatment strategies, inclusive of molecularly and country-specific relevant clinical trials.

QUEST trusts QIAGEN for expert interpretation of LeukoVantage assay 

To accelerate test turnaround times and ensure accurate reporting, Quest partnered with QIAGEN Precision Insights to provide expert interpretation of its LeukoVantage assay, a NGS test designed specifically for detecting clinically relevant variants in myeloid malignancies. 

Let us handle
your clinical

Request a consultation with a QCI Precision Insights expert to learn more about the service and how you can start sending your test results today.

QCI Interpret

Clinical decision support software enabling faster test turnaround times and higher confidence reporting for any indication on your sequencing platform

Clinical Analysis and Interpretation Services

Leverage the benefits of automation and expert support to improve test turnaround times and clinical reporting capabilities

Human Genome Mutation Database

Solve more cases faster, with data you can trust using HGMD Professional, the de facto standard resource for identifying inherited disease-causing mutations